In 2009 we formed a unique collaboration with Monash University’s Institute for Pharmaceutical Sciences (MIPS). The partnership draws upon some of the best minds in Australian pharmaceutical research and manufacturing, combining skills and ideas to develop “next-generation formulations and platform technologies”.
Monash University’s Institute for Pharmaceutical Sciences is Australia’s leading research centre for pharmaceutical science, as well as an educator for Australia’s next generation of leading scientists and engineers.
GSK, as a global pharmaceutical company, offers world-leading manufacturing capabilities, cross-jurisdictional commercial experience and a genuine commitment to innovative R&D.
The partnership established the MIPS-GSK Australian Centre of Innovation and Industrialisation (MIPS-GSK Centre), which has the mission of “securing a sustainable future for Australian pharmaceutical manufacturing through open innovation”, and seeks to develop medicines that are accessible for patients in emerging markets, focussing on operating a high-volume, low-cost manufacturing model.
Since launching in 2010, the MIPS-GSK Centre has provided a platform for both GSK and MIPS to develop advanced pharmaceutical products.
The efforts of the collaboration nationally recognised in 2013, when the Monash-GSK partnership was awarded by the Business-Higher Education Round Table (B-HERT) for Best Research & Development Collaboration and for Outstanding Excellence in Collaboration.
Commercialisation — Beyond manufacturing
GSK and Australia’s innovative R&D industry has much to gain from a collaboration that takes research through to industrialisation. This collaboration is unique as it combines and leverages the strengths of the leaders in the manufacturing and research communities. The result is a model that offers an end-to-end portfolio of specialised services across the entire supply chain process. Together, GSK and Monash are able to translate an existing medical intervention, or simply an idea for one, into a commercially-viable product that contributes to the Australian economy and wider community.
The benefits [of collaborations] include increased productivity, profitability and targeted export markets. In particular, collaboration between businesses and research organisations more than triples the likelihood of business productivity growth.
Ready examples of projects with potential for future commerciality include the development of dry-powder inhaler products, which carries significant export potential.
Since 2010 the partnership has collaborated on over 20 projects. Currently, there are eight proof-of-concept studies being conducted in GSK’s Boronia site.
The collaboration provides a developmental platform for Australia’s next generation of technical experts. GSK and Monash provide a number of educational opportunities for university students to be involved in the collaboration.
Since 2010, 85 tertiary-level students have gained real-world experience through Monash University’s internship pathways and GSK’s graduate program based in Boronia. For many, participation has enabled them to launch their research careers and transition into full-time employment within the industry.
The benefits are mutual for Monash and GSK: Monash students are given world-class facilities, networking opportunities within industry, and a platform to apply and test their technical knowledge against real-world challenges. GSK gains a competitive edge through early outreach to up-and-coming talent and access to world-class research facilities at Monash. Both organisations gain a fresh perspective from young minds who ‘think outside the square’ to overcome their shared challenges.